Scientific Online Resource System

Journal of Varna Medical College

Systemic Therapy For Skin And Soft Tissue Bacterial Infections In Childhood

Zheniya Stoyanova, Ilko Bakardzhiev

Abstract

Skin and soft tissue infections cover a wide variety of benign and life-threatening conditions. Some of them are treatable on an outpatient basis, while others require the use of intravenous antibiotics and surgery. When choosing a drug, it is advisable to perform a microbiological study and base on it to choose the most appropriate molecule from the different classes of antimicrobials. The main pathogens involved in these infections are Staphylococcus aureus and group A beta-hemolytic streptococcus, but enteral organisms also play a role, especially in nosocomial infections.

Skin and soft tissue infections have increased in frequency and severity in all age groups. The reasons for this are the increasing resistance of pathogenic microorganisms to many antibiotics in hospitalized patients and outpatients, the growing number of immunocompromised patients and the emergence of methicillin-resistant Staphylococcus aureus. These facts are relevant to treatment guidelines in order to address the increase in bacterial resistance and the choice of the type of therapy used.

For systemic treatment, drugs of choice are penicillin antibiotics, macrolides, cephalosporins, lincosamides, glycopeptides, aminoglycosides, tetracycline group, oxazolidinones, antifolate agents.


Keywords

skin infections, systemic antibiotic therapy, S. aureus, S. pyogenes, MRSA, resistance, macrolides, penicillin antibiotics, cephalosporins

Full Text


References

Fridkin SK, Hageman JC, Morrison M et ll. Active Bacterial Core Surveillance Program of the Emerging Infectious Program Network. Methicillin-resistant Staphylococcus aureus disease in three communities. N Eng J Med. 2005.352(14), 1436-1444.

Styers D, Sheehan DJ, Hogan P et al. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among S.aureus: 2005 status in USA. Ann Clin Microbiol. Antimicrob. 2006. 5, 2.

[Guideline] Stevens DL et all. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014update by the infectious desease society of America. 2014 Jul15. 59(2):10-52

Gorwitz RJ. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and update. Pediatr Infect Dis J. 2008 Oct. 27(10):925-6.

Bernard P. Management of common bacterial infections of the skin. Curr Opin Infect Dis. 2008 Apr.21(2): 122-8.

Mlynek KD, Callahan MT, Shimkevitch AV, Effects of Low-Dose Amoxicillin on Staphylococcus aureus USA300 Biofilms.2016 May; 60(5): 2639–2651.

Finland M. Changing patterns of susceptibility of common bacterial pathogens to antimicrobials. Ann Intern Med. 1972;76:1009–1036.

Wise PJ, Neu HC. Experience with amoxicillin: an overall summary of clinical trials in the United States. J Infect Dis. 1974;129(suppl):266–275.

Neu HC, Fu KP. Clavulanic acid; a novel inhibitor of beta-lactamases. Antimicrob Agents Chemother. 1978;14:650–655.

Rissor WL, Paplan SL, Mason EO. Treatment of soft tissue infections in children with amoxicillin-clavulanic acid combination or Cefaclor. Current Ther Res. 1985; 37:747–753.

Jaffe A, O'Brien CA, Reed MB. Randomized comparative evaluation of Augmentin and Cefaclor in paediatric skin and soft-tissue infections. Current Ther Res. 1985;338:160–168.

Wachs GN, Nelen TM, Parish LC. Comparison of Cefadroxil and amoxicillin/clavulanate in mild, moderate skin and skin-structure infections. Advances in Therapy. 1992; 9:69–80.

Vasconcellos AG, Leal RD, Silvany-Neto A, Nascimento-Carvalho CM. Oxacillin or cefalotin treatment of hospitalized children with cellulitis. Japanese Journal of Infectious Diseases, 01 Jan 2012, 65(1):7-12 PMID: 22274151

Stein M, Komerska J, Prizade M et al. Clindamycin resistance among Staphylococcus aureusstrains in Israel: implications for empirical treatment of skin and soft tissue infections. Int. J of Infect Dis. Volume 46, May 2016, Pages 18-21

Enright MC. The evolution of a resistant pathogen-the case of MRSA. Curr Opin Pharmacol 2003;3:474–479.

Jevons MP, Coe AW, Parker MT. Methicillin resistance in staphylococci. Lancet 1963;1:904–907.

Elek SD, Fleming PC. A new technique for the control of hospital cross infection. Lancet. 1960; ii: 569–72

Chen AE, Carrol KC, Diener-West Marie et al. Randomized Controlled Trial of Cephalexin Versus Clindamycin for Uncomplicated Pediatric Skin Infections. Pediatrics. 2011 Mar; 127(3): e573–e580.

Hepburn MJ, Dooley DP, Skidmore PJ et al. Comparison of short-course (5-days) and standart (10 days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004. 164:1669-74.

Simi Khangura, Jonathan Wallace, Niranjan Kissoon, Tanuja Kodeeswaran. Management of cellulitis in a pediatric emergency department. Pediatr Emerg Care. 2007 Nov;23(11):805-11. doi: 10.1097/PEC.0b013e31815a032f.

Rodriguez-Solares A, Perez-Gutierrez F, Prosperi J, et al. A comparative study of the efficacy, safety and tolerance of azithromycin, dicloxacillin and flucloxacillin in the treatment of children with acute skin and skin-structure infections. J Antimicrob Chemother. 1993;31(suppl E):103-109.

Montero L. A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections. J Antimicrob Chemother. 1996;37(suppl C):125-131.

Pacifico L, Cheisa C. Azithromycin in children: A critical review of the evidence, January 2002, Pages 54-76

Loren G. Miller, M.D., M.P.H., Robert S. Daum, M.D., C.M., C. Buddy Creech, M.D., M.P.H., Clindamycin versus Trimethoprim–Sulfamethoxazole for Uncomplicated Skin Infections. N Engl J Med. 2015; 372:1093-1103.

Silvia Garazzino,Pier-Angelo Tovo. Clinical experience with linezolid in infants and children. Journal of Antimicrobial Chemotherapy, Volume 66, Issue suppl_4, May 2011, Pages iv23–iv41.

Jungbluth GL, WelshmanIR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview, Pediatr Infect Dis J, 2003, vol.22, pg. S153-7.

Kearns GL, Jungbluth GL, Abdel-Rahman SM, et al. for the Pediatric Pharmacology Research Unit NetworkImpact of ontogeny on linezolid disposition in neonates and infants, Clin Pharmacol Ther , 2003, vol. 74, pg. 413-22.

Chiappini E, Conti C, Galli L, et al. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review, Clin Ther , 2010, vol. 32, р.66-88.

Sheldon L Kaplan, Jaime G Deville, Ram Yogev et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J. 2003 Aug;22(8):677-86. doi: 10.1097/01.inf.0000078160.29072.42.

Wible K, Tregnaghi M, Bruss J, et al. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children, Pediatr Infect Dis J , 2003, vol. 22, pg. 315-22.

Alzolibani AA, Al Robaee AA, Al Shobaili HA et al. Documentation of vancomycin-resistant Staphylococcus aureus (VRSA) among children with atopic dermatitis in the Qassim region, Saudi Arabi 2012 Sep;21(3):51-3.

Arfa P, Karimi A, Rafiei Tabatabaei S et al. A Prospective Study to Assess Vancomycin Serum Concentrations inPediatric Patients with Current Dosing Guidelines. Iranian Journal of Pharmaceutical Research : IJPR, 01 Jan 2016, 15(1):341-346

Bowen AC, Lilliebridge RA, Tong SY, Baird RW. Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole? J Clin Microbiol. 2012 Dec; 50(12):4067-72.

Harper GC, Cawston WC. The in-vitro determination of the sulphonamide sensitivity of bacteria. J Pathol Bacteriol 1945; 57:59–66.

Wilson AT. Method for testing in vitro resistance of group A hemolytic streptococci to sulfonamides. Proc Soc Exp Biol Med 1945; 58:130–3.

Bowen AC, Carapetis JR, Currie BJ et al. Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess. 2017 Nov2; 4(4): ofx232.


Refbacks

Font Size


|